Cover Image
市場調查報告書

Generex Biotechnology Corporation - 產品平台評估

Generex Biotechnology Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 214152
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Generex Biotechnology Corporation - 產品平台評估 Generex Biotechnology Corporation - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 30 Pages
簡介

Generex Biotechnology Corporation正在研究開發及商品化藥物遞送系統及技術,尤其更致力於季節性流感·病毒,及黑色素瘤、卵巢癌、HIV、HPV、過敏還有第一型糖尿病方面的巨大分子口腔用藥物遞輸系統技術。

本報告提供Generex Biotechnology Corporation的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Generex Biotechnology Corporation的基本資料

Generex Biotechnology Corporation概要

  • 主要資訊
  • 企業資料

Generex Biotechnology Corporation:R&D概要

  • 主要的治療範圍

Generex Biotechnology Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Generex Biotechnology Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Generex Biotechnology Corporation:藥物簡介

  • insulin human
  • AE-37
  • metformin hydrochloride
  • AE-AI Vaccine
  • AE-H Vaccine
  • AE-IG Vaccine
  • AE-M Vaccine
  • AE-O Vaccine
  • fentanyl
  • Low Molecular Weight Heparin
  • morphine sulfate

Generex Biotechnology Corporation:開發平台分析

Generex Biotechnology Corporation :各治療分類

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Generex Biotechnology Corporation:最近的開發平台趨勢

Generex Biotechnology Corporation:企業發表

Generex Biotechnology Corporation:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07901CDB

Summary

Global Markets Direct's, 'Generex Biotechnology Corporation - Product Pipeline Review - 2015', provides an overview of the Generex Biotechnology Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Generex Biotechnology Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Generex Biotechnology Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Generex Biotechnology Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Generex Biotechnology Corporation's pipeline products

Reasons to buy

  • Evaluate Generex Biotechnology Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Generex Biotechnology Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Generex Biotechnology Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Generex Biotechnology Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Generex Biotechnology Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Generex Biotechnology Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Generex Biotechnology Corporation Snapshot
    • Generex Biotechnology Corporation Overview
    • Key Information
    • Key Facts
  • Generex Biotechnology Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Generex Biotechnology Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Generex Biotechnology Corporation - Pipeline Products Glance
    • Generex Biotechnology Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Generex Biotechnology Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
  • Generex Biotechnology Corporation - Drug Profiles
    • insulin human
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AE-IG vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AE-O vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fentanyl citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • morphine sulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Generex Biotechnology Corporation - Pipeline Analysis
    • Generex Biotechnology Corporation - Pipeline Products by Target
    • Generex Biotechnology Corporation - Pipeline Products by Route of Administration
    • Generex Biotechnology Corporation - Pipeline Products by Molecule Type
    • Generex Biotechnology Corporation - Pipeline Products by Mechanism of Action
  • Generex Biotechnology Corporation - Recent Pipeline Updates
  • Generex Biotechnology Corporation - Dormant Projects
  • Generex Biotechnology Corporation - Company Statement
  • Generex Biotechnology Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Generex Biotechnology Corporation, Key Information
  • Generex Biotechnology Corporation, Key Facts
  • Generex Biotechnology Corporation - Pipeline by Indication, 2015
  • Generex Biotechnology Corporation - Pipeline by Stage of Development, 2015
  • Generex Biotechnology Corporation - Monotherapy Products in Pipeline, 2015
  • Generex Biotechnology Corporation - Phase III, 2015
  • Generex Biotechnology Corporation - Phase I, 2015
  • Generex Biotechnology Corporation - Pipeline by Target, 2015
  • Generex Biotechnology Corporation - Pipeline by Route of Administration, 2015
  • Generex Biotechnology Corporation - Pipeline by Molecule Type, 2015
  • Generex Biotechnology Corporation - Pipeline Products by Mechanism of Action, 2015
  • Generex Biotechnology Corporation - Recent Pipeline Updates, 2015
  • Generex Biotechnology Corporation - Dormant Developmental Projects,2015
  • Generex Biotechnology Corporation, Subsidiaries

List of Figures

  • Generex Biotechnology Corporation - Pipeline by Top 10 Indication, 2015
  • Generex Biotechnology Corporation - Pipeline by Stage of Development, 2015
  • Generex Biotechnology Corporation - Monotherapy Products in Pipeline, 2015
  • Generex Biotechnology Corporation - Pipeline by Top 10 Target, 2015
  • Generex Biotechnology Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Generex Biotechnology Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Generex Biotechnology Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top